Outcomes in women with breast cancer by molecular subtype, from past hospital records
Reviews past records of women with breast cancer, comparing outcomes across molecular subtypes.
Plain-language title generated from the registry record
Registry title: Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Key facts
- Where
- Bogotá, ColombiaSee the site
Where in Colombia
- Hospital Universitario Fundación Santa Fe de BogotáBogotá, ColombiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación Santa Fe de Bogota
- Trial code
- NCT07856225
- Record updated
- 2 October 2026
- Original description
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments. In Colombia, there is limited information that integrates the clinical, treatment, sociodemographic and contextual characteristics of each subtype, and limited data on the direct medical costs of breast cancer care.Read full original descriptionShow less
Evaluation of Clinical and Therapeutic Outcomes According to Molecular Subtype in Patients With Breast Cancer: Experience of Fundación Santa Fe de Bogotá
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments. In Colombia, there is limited information that integrates the clinical, treatment, sociodemographic and contextual characteristics of each subtype, and limited data on the direct medical costs of breast cancer care.
This retrospective cohort study will review the medical records of women 18 years or older with biopsy-confirmed breast cancer and a documented molecular subtype who were treated at Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024. It will describe each molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, triple-negative and HER2-low) and evaluate the association of clinical, molecular and treatment characteristics with overall survival, progression-free survival, recurrence, treatment response and grade 3-4 adverse events. It will also explore the impact of the COVID-19 pandemic and health insurance regimen on outcomes, and estimate direct medical costs of breast cancer care by clinical stage and phase of care. The investigators will not assign or modify any treatment.
Inclusion: Patients older than 18 years with a histopathologically confirmed diagnosis of breast cancer; Treated at Fundación Santa Fe de Bogotá between January 1, 2014 and December 31, 2024; Available record of the tumor molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched or triple-negative), determined by immunohistochemistry and/or in situ hybridization.
Exclusion: Incomplete or missing information on molecular subtype, treatment received or clinical outcomes; Lesions of uncertain malignant potential or in situ tumors; Metastatic tumors from another primary site involving the breast (for example, breast metastases from another primary tumor); Oncology follow-up outside the institution without adequate traceability of clinical outcomes.